LM11A-31调节p75神经营养因子受体抑制炎症和RhoA激酶通路预防糖尿病视网膜血管渗漏
该研究在链脲佐菌素诱导的糖尿病小鼠中,口服p75NTR调节剂LM11A-31(50 mg/kg/天)4周,可减轻proNGF蓄积、保护血视网膜屏障;在人视网膜内皮细胞中,突变型proNGF(10 ng/ml)增加细胞通透性并降低紧密连接蛋白表达,而LM11A-31可抑制proNGF介导的RhoA激活、occludin磷酸化及细胞通透性。结论提示靶向p75NTR信号可能为糖尿病黄斑水肿提供口服非侵入性治疗策略。
要点
- 糖尿病小鼠口服LM11A-31可减轻proNGF蓄积并保护血视网膜屏障。
- 突变型proNGF(10 ng/ml)增加人视网膜内皮细胞通透性并降低ZO-1和claudin-5表达。
- LM11A-31抑制proNGF介导的RhoA激活、occludin磷酸化和细胞通透性。
核心结论
- 靶向p75NTR信号使用口服生物利用的受体调节剂LM11A-31,可能为糖尿病黄斑水肿提供有效、安全、非侵入性的治疗策略。
研究设计与样本
- 雄性C57BL/6J小鼠经链脲佐菌素诱导糖尿病,2周后口服LM11A-31(50 mg/kg/天)或生理盐水(NaCl 154 mmol/l)4周。
- 在人视网膜内皮细胞中,检测突变型proNGF(10 ng/ml)在有无LM11A-31或Rho激酶抑制剂Y-27632时的直接效应。
主要发现
- 糖尿病触发血视网膜屏障破坏,循环和视网膜TNF-α、IL-1β水平显著升高,视网膜NGF显著降低,VEGF和proNGF表达升高,RhoA激活。
- LM11A-31治疗显著减轻proNGF蓄积并保护血视网膜屏障完整性。
- 突变型proNGF(10 ng/ml)增加人视网膜内皮细胞通透性,显著降低紧密连接蛋白ZO-1和claudin-5表达,不依赖炎症介质或细胞死亡。
- LM11A-31显著抑制proNGF介导的RhoA激活、occludin丝氨酸490磷酸化和细胞通透性。
- proNGF诱导ZO-1在细胞壁重新分布和F-actin应力纤维形成,LM11A-31可减轻这些效应。
临床怎么用
- LM11A-31作为口服p75NTR调节剂,可能用于预防糖尿病诱导的血视网膜屏障破坏。
- 靶向p75NTR/RhoA下游信号可能成为糖尿病黄斑水肿的非侵入性治疗方向。
局限性
- 研究仅在小鼠模型和人视网膜内皮细胞中进行,尚未在人体临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Breakdown of the inner blood-retinal barrier (BRB) is an early event in the pathogenesis of diabetic macular oedema, that eventually leads to vision loss. We have previously shown that diabetes causes an imbalance of nerve growth factor (NGF) isoforms resulting in accumulation of its precursor proNGF and upregulation of the p75 neurotrophin receptor (p75NTR), with consequent increases in the activation of Ras homologue gene family, member A (RhoA). We also showed that genetic deletion of p75NTR in diabetes preserved the BRB and prevented inflammatory mediators in retinas. This study aims to examine the therapeutic potential of LM11A-31, a small-molecule p75NTR modulator and proNGF antagonist, in preventing diabetes-induced BRB breakdown. The study also examined the role of p75NTR/RhoA downstream signalling in mediating cell permeability. METHODS: Male C57BL/6 J mice were rendered diabetic using streptozotocin injection. After 2 weeks of diabetes, mice received oral gavage of LM11A-31 (50 mg kg-1 day-1) or saline (NaCl 154 mmol/l) for an additional 4 weeks. BRB breakdown was assessed by extravasation of BSA-AlexaFluor-488. Direct effects of proNGF were examined in human retinal endothelial (HRE) cells in the presence or absence of LM11A-31 or the Rho kinase inhibitor Y-27632. RESULTS: Diabetes triggered BRB breakdown and caused significant increases in circulatory and retinal TNF-α and IL-1β levels. These effects coincided with significant decreases in retinal NGF and increases in vascular endothelial growth factor and proNGF expression, as well as activation of RhoA. Interventional modulation of p75NTR activity through treatment of mouse models of diabetes with LM11A-31 significantly mitigated proNGF accumulation and preserved BRB integrity. In HRE cells, treatment with mutant proNGF (10 ng/ml) triggered increased cell permeability with marked reduction of expression of tight junction proteins, zona occludens-1 (ZO-1) and claudin-5, compared with control, independent of inflammatory mediators or cell death. Modulating p75NTR significantly inhibited proNGF-mediated RhoA activation, occludin phosphorylation (at serine 490) and cell permeability. ProNGF induced redistribution of ZO-1 in the cell wall and formation of F-actin stress fibres; these effects were mitigated by LM11A-31. CONCLUSIONS/INTERPRETATION: Targeting p75NTR signalling using LM11A-31, an orally bioavailable receptor modulator, may offer an effective, safe and non-invasive therapeutic strategy for treating macular oedema, a major cause of blindness in diabetes.
引用
- Elshaer SL, Alwhaibi A, Mohamed R, et al. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019. PMID: 31073629. doi:10.1007/s00125-019-4885-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。